It's Ethical to Pay COVID VolunteersRead the rest of this entry »
It is ethically appropriate to pay volunteers who are intentionally infected with the COVID virus as part of clinical research, says an international panel of experts.
In a report published in the American Journal of Bioethics, the group of ethicists, lawyers, academics, laymen and others from the UK, United States, and Canada found that paying participants in a COVID study should be decided the same way as other human …
Study Says Vaccination Is Saving Children’s LivesRead the rest of this entry »
Vaccinations against such common diseases as measles, hepatitis and human papillomavirus saved 37 million deaths in low- and middle-income countries over the last two decades and by 2030 will have prevented 32 million more.
And no group has benefited more than the youngest children.
According to research reported last month in The Lancet, deaths among children under 5 from the 10 diseases i n the study would have been …
Big Pharma Ranked On Access to MedicinesRead the rest of this entry »
In a report scoring the efforts of 20 global pharmaceutical companies in providing access to their medicines the industry came in for some rare praise, as well as a bit of scolding for too often putting poor countries last.
“After years of encouraging access planning, we are now seeing a strategic shift in this direction [of inclusion] by pharma companies,” said Jayasree K. Iyer, executive director of the Access …
COVID Has Forever Changed How Vaccines Are DevelopedRead the rest of this entry »
The vaccine rollout may be progressing too slowly, but that there’s a vaccine so soon at all is a tribute to the single-focus of scientists and the biotech industry.
The way the Pfizer and Moderna vaccines were developed “are revolutionary,” says Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization.
In a wide-ranging interview with Steve Forbes and published on Forbes online, she said, “The platforms that have …
Can Biotech Sustain the Changes of the Last Year?Read the rest of this entry »
The COVID pandemic has changed the biotech industry in a positive way, demonstrating it can act quickly and decisively to develop vaccines against the SARS-CoV-2 virus.
"We have seen the transformative power of science,” said Dr. Michelle McMurry-Heath, PhD, president and CEO of the Biotechnology Innovation Organization (BIO).
She, and other speakers presenting in advance of last week's virtual Biotech Showcase, predicted the impact of the pandemic on the industry …
Here’s How to Land That First Clinical Research JobRead the rest of this entry »
Starting a career in clinical research is challenging. Armed with a relevant college degree, an internship or two and even with a certificate in clinical management, landing an entry-level job isn’t easy.
Says Kunal Sampat, MNA, ACRP-CP and host of the Clinical Trial Podcast, “Employers want applicants to have relevant CRA experience.”
That’s the old chicken and egg dilemma: How do you get the experience without having a job and …
What’s the Difference Between the COVID Vaccines?Read the rest of this entry »
With the approval last month of the Moderna vaccine by the Food and Drug Administration, we now have two COVID-19 vaccines available. Two more – one from Johnson & Johnson the other from AstraZeneca – are on the way and could be approved as soon as February.
Healthcare workers, residents of nursing facilities and some first responders have already received the Pfizer vaccine, the first one approved by the FDA. …
New Group Will Promote Decentralized Clinical TrialsRead the rest of this entry »
Several of the world’s healthcare, bioscience and pharmaceutical firms, including such global leaders as AstraZeneca, Pfizer and Biogen have joined together to accelerate the adoption of decentralized clinical trials and research.
In the planning stage before the coronavirus pandemic, the Decentralized Trials & Research Alliance (DTRA) formally announced its founding this month. With an initial membership of some 50 organizations, the alliance declared its mission to “make clinical trial participation …
The ‘Remarkable’ Rise of Biosimilar DrugsRead the rest of this entry »
“Will 2021 be another break-through year for biosimilars?” asks Forbes in an article this month.
Written by healthcare analyst Joshua Cohen Pd.D., the article discusses the rising use of biosimilars which he calls “remarkable.”
“The latest data show that physician-administered biosimilar drugs are successfully displacing their reference biologics,” Cohen writes. “Newer biosimilars are being adopted faster than before, due in large part to declining prices.”
Biosimilars are sometimes confused with …
Clinical Investigators Need to Know the Privacy RulesRead the rest of this entry »
Distracted by the COVID pandemic, clinical investigator sites that haven’t been paying attention to new privacy laws may find it difficult to conduct trials in 2021.
“Nine out of ten investigator sites in the U.S. don’t know anywhere near enough,” and “don’t have the right tools to be in compliance,” says an article on the Association Of Clinical Research Professionals blog.
An interview with Al O. Pacino II, president …